Tags

Type your tag names separated by a space and hit enter

Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats.
Eur J Pharmacol 2015; 765:482-7EJ

Abstract

Recent studies suggest a possible link between type 2 diabetes and Alzheimer's disease (AD). Glucogan-like peptide 1 (GLP-1) facilitates insulin release from pancreas under hyperglycemic conditions. In addition to its metabolic effects, GLP-1 and its long-lasting analogs, including exenatide can stimulate neurogenesis and improve cognition in rodent AD model. The aim of the present study was to investigate the effects of exenatide on hippocampal cellularity, cognitive performance and inflammation response in a rat model of AD. Fourteen rats were used to create AD model using intracerebroventricular (ICV) streptozotocin (STZ) infusion while 7 rats were administered 0.9% NaCl only (sham-operated group). Following stereotaxic surgery, STZ received rats were randomly distributed into two groups, and treated with either saline or exenatide 20 µgr/kg/day through intraperitoneally for two weeks. Then, cognitive performance (passive avoidance learning), brain tumor necrosis factor alpha (TNF-α) levels, choline acetyltransferase (ChAT) activity and hippocampal neuronal count were determined. While the brain TNF-α levels were significantly high in the saline-treated STZ group, exenatide treatment suppressed the increase in TNF-α levels. Saline-treated STZ group showed reduced ChAT activity compared to sham group. However, exenatide significantly preserved brain ChAT activity. The cognitive performance was also impaired in saline group while exenatide improved memory in rats. Moreover, exenatide treatment significantly prevented the decrease in hippocampal neurons. Overall, the results of the present study clearly indicated exenatide might have beneficial effects on impaired cognitive performance and hippocampal neuronal viability in AD by suppressing the inflammation response and increasing cholinergic activity.

Authors+Show Affiliations

Department of Neurology, Turhal State Hospital, Tokat, Turkey. Electronic address: solmaz.volkan@yahoo.com.Department of Neurology, Giresun State Hospital, Giresun, Turkey.Department of Histology & Embryology, Ege University School of Medicine, İzmir, Turkey.Department of Histology & Embryology, Ege University School of Medicine, İzmir, Turkey.Department of Physiology, Ege University School of Medicine, İzmir, Turkey.Department of Physiology, Istanbul Bilim University School of Medicine, İstanbul, Turkey.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26386291

Citation

Solmaz, Volkan, et al. "Exenatide Reduces TNF-α Expression and Improves Hippocampal Neuron Numbers and Memory in Streptozotocin Treated Rats." European Journal of Pharmacology, vol. 765, 2015, pp. 482-7.
Solmaz V, Çınar BP, Yiğittürk G, et al. Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur J Pharmacol. 2015;765:482-7.
Solmaz, V., Çınar, B. P., Yiğittürk, G., Çavuşoğlu, T., Taşkıran, D., & Erbaş, O. (2015). Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. European Journal of Pharmacology, 765, pp. 482-7. doi:10.1016/j.ejphar.2015.09.024.
Solmaz V, et al. Exenatide Reduces TNF-α Expression and Improves Hippocampal Neuron Numbers and Memory in Streptozotocin Treated Rats. Eur J Pharmacol. 2015 Oct 15;765:482-7. PubMed PMID: 26386291.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. AU - Solmaz,Volkan, AU - Çınar,Bilge Piri, AU - Yiğittürk,Gürkan, AU - Çavuşoğlu,Türker, AU - Taşkıran,Dilek, AU - Erbaş,Oytun, Y1 - 2015/09/16/ PY - 2015/04/15/received PY - 2015/09/14/revised PY - 2015/09/15/accepted PY - 2015/9/20/entrez PY - 2015/9/20/pubmed PY - 2016/8/9/medline KW - Alzheimer's disease KW - Choline acetyltransferase KW - Exenatide KW - Streptozotocin KW - Tumor necrosing factor-alpha SP - 482 EP - 7 JF - European journal of pharmacology JO - Eur. J. Pharmacol. VL - 765 N2 - Recent studies suggest a possible link between type 2 diabetes and Alzheimer's disease (AD). Glucogan-like peptide 1 (GLP-1) facilitates insulin release from pancreas under hyperglycemic conditions. In addition to its metabolic effects, GLP-1 and its long-lasting analogs, including exenatide can stimulate neurogenesis and improve cognition in rodent AD model. The aim of the present study was to investigate the effects of exenatide on hippocampal cellularity, cognitive performance and inflammation response in a rat model of AD. Fourteen rats were used to create AD model using intracerebroventricular (ICV) streptozotocin (STZ) infusion while 7 rats were administered 0.9% NaCl only (sham-operated group). Following stereotaxic surgery, STZ received rats were randomly distributed into two groups, and treated with either saline or exenatide 20 µgr/kg/day through intraperitoneally for two weeks. Then, cognitive performance (passive avoidance learning), brain tumor necrosis factor alpha (TNF-α) levels, choline acetyltransferase (ChAT) activity and hippocampal neuronal count were determined. While the brain TNF-α levels were significantly high in the saline-treated STZ group, exenatide treatment suppressed the increase in TNF-α levels. Saline-treated STZ group showed reduced ChAT activity compared to sham group. However, exenatide significantly preserved brain ChAT activity. The cognitive performance was also impaired in saline group while exenatide improved memory in rats. Moreover, exenatide treatment significantly prevented the decrease in hippocampal neurons. Overall, the results of the present study clearly indicated exenatide might have beneficial effects on impaired cognitive performance and hippocampal neuronal viability in AD by suppressing the inflammation response and increasing cholinergic activity. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/26386291/Exenatide_reduces_TNF_α_expression_and_improves_hippocampal_neuron_numbers_and_memory_in_streptozotocin_treated_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(15)30255-7 DB - PRIME DP - Unbound Medicine ER -